Navigation Links
EntreMed Commences Phase 2 Trial For ENMD-2076 In Ovarian Clear Cell Carcinomas
Date:10/31/2013

ROCKVILLE, Md., Oct. 31, 2013 /PRNewswire/ -- EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today the commencement of a multi-center Phase 2 study entitled "Phase II Study of Oral ENMD-2076 Administered to Patients with Ovarian Clear Cell Carcinomas."  The study is led by principal investigator Amit M. Oza, MD at Princess Margaret Cancer Centre in Toronto, Canada with participation of up to seven additional cancer centers in Canada and the United States.  More information about the clinical trial can be found at www.clinicaltrials.gov.  

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO )

Amit M. Oza, MD, principal investigator of the study, commented, "Ovarian clear cell carcinomas (OCCC) account for approximately 5-13% of all epithelial ovarian cancers and compared to other subtypes, are associated with poorer prognosis and can be resistant to conventional platinum-based chemotherapy.  It presents a considerable clinical challenge and there is a need to develop new therapeutics in the management of this disease.  ENMD-2076 has demonstrated single agent activity in tumor models of multiple cancers including ovarian cancer.  In a recent Phase 2 trial where ENMD-2076 was administered to platinum-resistant recurrent ovarian cancer patients, some OCCC patients had prolonged disease control, suggesting that it may be effective in this subset of patients. We want to explore this further.  The purpose of this study is to examine the response and PFS rates of
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EntreMed Reports Second Quarter 2013 Financial Results
2. EntreMed Initiates Crossover Bioavailability And Food Effect Study Of ENMD-2076 Dosage Form To Be Used For Pivotal/Registration Clinical Trials
3. EntreMed Reports First Quarter 2013 Financial Results
4. Patent Issued In China For EntreMeds Lead Drug Candidate ENMD-2076
5. Patent Issued In U.S. For EntreMeds 2ME2 In Rheumatoid Diseases
6. EntreMed Announces Changes to Board of Directors and CEO Appointment
7. EntreMed Reports Fourth Quarter And Year-End 2012 Financial Results And Business Outlook For 2013
8. EntreMed To Raise $10.7 Million In Registered Direct Offering
9. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
10. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
11. EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... SANTA ROSA, Calif. , Oct. 24, 2014 /PRNewswire-USNewswire/ ... he was ordering large quantities of multiple controlled substances, ... patient care. They also reported that Dr. Gurney was ... Medical Board reported that one of his employees said ... his care and treatment of patients." Dr. ...
(Date:10/25/2014)... Burzynski Research Institute, Inc. (BRI) announced today that the ... company permission to conduct an open-label study of Antineoplastons ... age with a diffuse intrinsic brainstem glioma (DIPG). Study ... groups based on their age and whether or not ... study endpoint is a decrease in the size of ...
(Date:10/22/2014)... , Oct. 22, 2014  Cephasonics, a technology-innovation ... introduction of the cQUB™-1 (cQuest Ultrasound Box™-1), the first ... systems designed and manufactured by Cephasonics for purchase by ... model number. Cephasonics will be showcasing the cQUB-1 for ... this week in Chongqing, China ...
Breaking Medicine Technology:Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 2Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 3Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3
... , Inc., a full-service contract research organization (CRO), and ... combat the growing issue of antibiotic resistance, have partnered ... walk to benefit the Cystic Fibrosis (CF) Foundation through ... Aptalis Pharma) are also working together on clinical trials ...
... May 2, 2012  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ... March 31, 2012.  For the first quarter of 2012, the ... per share, compared with a net income of $2.9 million, ... 2011. This $3.8 million change in operating results is primarily ...
Cached Medicine Technology:Synteract and Rempex Partner in "Great Strides" Walk to Support Cystic Fibrosis Cure 2Neurocrine Biosciences Reports First Quarter 2012 Results 2Neurocrine Biosciences Reports First Quarter 2012 Results 3Neurocrine Biosciences Reports First Quarter 2012 Results 4Neurocrine Biosciences Reports First Quarter 2012 Results 5Neurocrine Biosciences Reports First Quarter 2012 Results 6
(Date:10/25/2014)... shorter, darker days can trigger a type of depression, ... People affected by seasonal affective disorder, also ... even have trouble getting out of bed. In extreme ... Halaris, a professor in the department of psychiatry and ... Medicine. "Seasonal affective disorder should not be taken ...
(Date:10/22/2014)... October 22, 2014 On Saturday, October 25, ... fourth annual family health and fitness fair ¡Vive tu vida! ... activity and good nutrition for better health and wellness for ... is free and open to the public, will be held ... from 9:00 am to 1:00 pm. , “¡Vive tu ...
(Date:10/22/2014)... Medical Solutions , the nation’s ... announce that our co-founder and CFO, Scott Anderson, ... 100 for 2014. Anderson was also named to ... in the staffing industry,” in 2013.     , Under ... staffing company in the U.S., was named a ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 For Dr. Iris ... make money; it’s an extension of her life’s mission. Her ... venture as the owner of FirstLight HomeCare, make it clear ... important to me that my work makes a difference in ... an entrepreneurial spirit, so after much research, I felt ready ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- The ... passengers arriving from Ebola-affected nations of West Africa ... screen them for infection with the virus. ... Jeh Johnson noted that 94 percent of air ... land at one of these five airports -- ...
Breaking Medicine News(10 mins):Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3
... better control of disease when chemo is targeted to specific ... The number one cancer killer, lung cancer, may be more ... tumors with key genetic traits, a new study finds. , ... that, overall, 46 percent of patients with stage IV (advanced) ...
... from a sentinel lymph node removed during surgery is a ... false negatives, which means the node, when analyzed under a ... occur in the patient. The sentinel node is the first ... Now, researchers from Georgetown Lombardi Comprehensive Center say that they ...
... ... a Build-a-Beam interactive feature, Keilhauer,s new microsite for Beam Seating makes specifying beam seating ... ... and Simple Beam seating expand the original series to such an extent it can ...
... ... restrictions, and more severe problems, like sleep apnea, can increase the risk of heart attack ... Denver, ... are diagnosed with sinusitis, and many of these people find long-term relief and a new ...
... ... ... 18, 2010 -- Allegheny Medical Integrated Health Services ( http://www.alleghenymedical.com/ ), one of Pittsburgh,s ... mission is to build better health for every aspect of an individual,s life. ...
... ... Touchstone Products LLC is proud to announce the unveiling of its ... affordable prices directly to the American Consumer. TouchstoneSaunas.com offers premium ... your home. Constructed from the highest quality materials to provide ...
Cached Medicine News:Health News:Matching Tumor Types to Drugs Boosts Lung Cancer Outcomes 2Health News:Matching Tumor Types to Drugs Boosts Lung Cancer Outcomes 3Health News:Routine breast cancer biopsy might predict lymph node cancer spread 2Health News:Keilhauer's Expanded Beam Seating Launches With its Own Microsite 2Health News:Keilhauer's Expanded Beam Seating Launches With its Own Microsite 3Health News:Breathing Obstructions Caused by Sinusitis can Require Surgery, says Denver's Nose Doc 2Health News:Breathing Obstructions Caused by Sinusitis can Require Surgery, says Denver's Nose Doc 3Health News:Allegheny Medical's Occupational Health Services Helps Employers Build a Healthier Workforce 2Health News:Allegheny Medical's Occupational Health Services Helps Employers Build a Healthier Workforce 3Health News:Touchstone Saunas Goes Online to Provide Premium Quality Infrared Saunas 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: